Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (26911)	12/16/1998 9:41:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 32384

Your search feature was very useful-- I already have aria and gene (yes, I am asthmatic), but the stocks have been real dogs, and I am beginning to think my investments were a bit foolhardy--exciting sounding press, but perhaps years away from any progress, any thoughts? Here is what GENE said in a press release ''We have accomplished a great deal in a short timeframe,'' said Robert J. Hennessey, Chairman, President and CEO. ''Together, we have completed accumulation of extensive family resources, collected valuable genetic data and identified chromosomal regions for intensive gene discovery exploration. By increasing the size of the program now, we will be able to expedite the process of identifying asthma susceptibility genes to develop therapeutics based on the genetic cause of this complex disease.'' Announced in December 1996, this potential $67 million alliance calls for Genome Therapeutics to employ its high-throughput positional cloning, genomic sequencing and bioinformatics capabilities to identify genes and associated proteins that can be utilized by Schering-Plough to develop new pharmaceuticals for asthma. Two milestone announcements have been made in 1998. biz.yahoo.com ...and here is what ARIA says on it's website ARIAD has taken a novel approach to the treatment of allergy and asthma. Rather than blocking a single mediator after its release from the activated mast cell, ARIAD is developing small-molecule compounds designed to target the signaling pathway inside the mast cell that is responsible for the production and release of multiple allergic mediators. This strategy may block a broad array of allergic mediators prior to their release into the bloodstream. ARIAD is targeting a critical protein in the mast cell activation pathway called Syk, a protein tyrosine kinase that is responsible for the activation of signaling pathways in mast cells that lead to the release of allergic mediators. ARIAD is developing small molecules designed to bind to the SH2 or kinase domains of Syk thereby blocking interaction with the IgE receptor complex. By blocking this initial interaction in the signal transduction pathway, it may be possible to down-regulate the production and release of multiple allergic mediators with a single drug. ariad.com but I am beginning to think that what I really need is to take my money out of these stocks and buy myself a rigourous course of allergy shots--for which I myself must pay--can you beleive the HMO's, (expletive deleted). Any thoughts about aria and gene, which of the biotechs do you think is more likely to make an asthma breakthrough? Of course I am just being funny, I can own the stocks and get the shots too, heh heh. --Mike